Trials / Not Yet Recruiting
Not Yet RecruitingNCT06111326
BC3402 in Combination With Durvalumab in Patients With Advanced Hepatocellular Carcinoma
A Phase Ib/II Clinical Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BC3402 in Combination With Durvalumab in Patients With Advanced Hepatocellular Carcinoma
- Status
- Not Yet Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 83 (estimated)
- Sponsor
- Biocity Biopharmaceutics Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Phase Ib: Dose exploration: To assess the safety, tolerability, and determine the recommended Phase 2 dose (RP2D) of BC3402 in combination with durvalumab in subjects with advanced hepatocellular carcinoma (HCC) Phase II: Dose Expansion: To assess the antitumor activity of BC3402 in combination with durvalumab in subjects with advanced HCC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BC3402 injection | Intravenous infusion, once every 2 weeks, 4 weeks/cycle. |
| DRUG | Durvalumab injection | Intravenous infusion, once every 4 weeks, 4 weeks/cycle. |
Timeline
- Start date
- 2023-10-01
- Primary completion
- 2024-08-01
- Completion
- 2026-05-01
- First posted
- 2023-11-01
- Last updated
- 2023-11-01
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06111326. Inclusion in this directory is not an endorsement.